Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310284 | 1.00 | SIGMAR1 (0.51) | SIGMAR1LTA4HTACR1KDM4EMEN1 | |
| SCHEMBL14085915 | 1.00 | SIGMAR1 (0.51) | SIGMAR1LTA4HTACR1KDM4EMEN1 | |
| SCHEMBL10675682 | 0.88 | SIGMAR1 (0.49) | SIGMAR1LTA4HTACR1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL11446780 | 0.88 | SIGMAR1 (0.49) | SIGMAR1LTA4HTACR1KDM4EMEN1 | |
| SCHEMBL29289212 | 0.88 | SIGMAR1 (0.49) | SIGMAR1LTA4HTACR1KDM4EMEN1 | |
| SCHEMBL5201106 | 0.87 | SIGMAR1 (0.47) | SIGMAR1LTA4HTACR1KDM4EMEN1 | |
| SCHEMBL6335455 | 0.87 | TACR1 (0.55) | SIGMAR1LTA4HTACR1KDM4EACHE | |
| SCHEMBL6335458 | 0.87 | TACR1 (0.55) | SIGMAR1LTA4HTACR1KDM4EACHE | |
| SCHEMBL16026440 | 0.86 | SIGMAR1 (0.46) | SIGMAR1LTA4HTACR1KDM4EMEN1 | |
| SCHEMBL3494925 | 0.86 | SIGMAR1 (0.46) | SIGMAR1LTA4HTACR1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| CN-102060809-B | Rhein derivatives and preparation and application thereof | CHANGZHOU HI TECH DISTR MULTIPLE DIMENSION INDUSTRY TECHNOLOGY INST CO LTD | 2015-05-20 | — | — | CN | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| CN-101638423-B | Phloridzin derivative as well as preparation method and application thereof | 3D IND TECHNOLOGY RES INST CO LTD OF CHANGZHOU HIGH TECH IND DEV ZONE | 2012-09-05 | — | — | CN | disclosed |
| CN-102060809-A | Rhein derivatives and preparation and application thereof | CHANGZHOU HI TECH DISTR MULTIPLE DIMENSION INDUSTRY TECHNOLOGY INST CO LTD | 2011-05-18 | — | — | CN | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-101638423-A | Phloridzin derivative as well as preparation method and application thereof | 3D IND TECHNOLOGY RES I CO LTD | 2010-02-03 | — | — | CN | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1685115-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-6967201-B1 | for increasing activation of the 5-HT2C receptor in mammals; treatment of depression, obesity, bulimia, premenstrual syndrome, alcoholism, tobacco abuse, panic disorder | ELI LILLY AND COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| WO-2005042501-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | disclosed |
| EP-1204654-B1 | BENZOFURYLPIPERAZINES: 5-HT2C SEROTONIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | SIGMAR1 74/4885LTA4H 2843/4885TACR1 94/4885 |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | SIGMAR1 1018/4885LTA4H 1466/4885TACR1 898/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | SIGMAR1 2945/4885LTA4H 1220/4885TACR1 1243/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | SIGMAR1 1018/4885LTA4H 1466/4885TACR1 898/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | SIGMAR1 1138/4885LTA4H 1769/4885TACR1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.